BCR/ABL Quantitative RT-PCR Assay Now Offered by CBLPath

Molecular Test an Important Tool in Diagnosis and Management of CML


RYE BROOK, N.Y. — CBLPath, a Sonic Healthcare USA laboratory, is pleased to announce the addition of BCR/ABL quantitative RT-PCR analysis to its growing in-house molecular test menu.

A reciprocal translocation between chromosomes 9 and 22 results in the generation of the BCR/ABL fusion gene and gives rise to the "Philadelphia chromosome" (Ph). The resultant BCR/ABL protein is a constitutively active tyrosine kinase that stimulates the proliferation of immature myeloid cells. The Ph chromosome is a highly sensitive indicator of CML, since 95% of people with CML have this chromosomal abnormality. However, the presence of the Ph chromosome is not sufficiently specific to diagnose CML, since it is also found in acute lymphoblastic leukemia (ALL, 25–30% in adult and 2–10% in pediatric cases) and occasionally in acute myelogenous leukemia (AML).

CML will progress from a chronic phase to an accelerated phase within several years if left untreated. Survival is typically only a few months once the accelerated phase or blast crisis occurs. The identification of the Philadelphia chromosome has had a significant impact on the treatment of CML, leading to the development of targeted tyrosine kinase inhibitors (TKIs) such as imatinib, dasatanib and nilotinib. The long-term prognosis for CML is usually positive with use of TKI therapy.

CBLPath’s new BCR/ABL quantitative RT-PCR assay detects the level of BCR/ABL transcript in the blood of CML patients. Monitoring BCR/ABL levels in patients receiving TKI therapy is the gold standard for the management of CML and for assessment of response to therapy. This molecular assay uses the most up-to-date technology to deliver definitive diagnostic and prognostic information, aiding physicians in the care of their CML patients.

"CBLPath is committed to continuing to provide physicians with the best tools and information to diagnose, manage and treat their patients" explained CBLPath Co-CEO and Chief Medical Officer, Dr. Carlos D. Urmacher, FCAP, FASCP. "The addition of BCR-ABL further strengthens our leading hematopathology offering and will provide vital information for the management of CML patients."

To speak with a local CBLPath representative about ordering BCR/ABL quantitative RT-PCR testing, call 877.225.7284. To see the company's entire array of tests, visit www.CBLPath.com and click Test Menu.

About CBLPath
CBLPath, a Sonic Healthcare USA laboratory, is a national specialty lab with a unique leadership position in the convergence of anatomic, molecular and digital pathology. Beginning from a clinical perspective, we harness molecular testing and digital pathology on an anatomic pathology foundation. CBLPath is committed to helping our clients deliver better medicine, faster. At our core are pathologists; excited about technology and innovation and its promise of helping patients. Through the Best Practice™ Partnership Program we help our pathologist-clients effectively compete against centralized reference laboratories, grow their Practice and remain independent — Keeping Medicine Local™. We provide our subspecialty physician clients comprehensive diagnostics and timely, accurate reports enabling the best patient care. For more about the company, please visit www.CBLPath.com.